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Abstract
Background: Oxidized lipoprotein(a) (oxLp(a)) can be a more potent marker of atherogenesis than native Lp(a),
although Lp(a) is considered to be a risk factor for atherosclerotic diseases. Limited clinical data are available
regarding the significance of oxLp(a) in atherosclerotic manifestations. This study aimed to investigate the
association between the serum oxLp(a) and carotid artery intima-media thickness (CIMT), in comparison to the
serum Lp(a) levels, among asymptomatic subjects.
Methods: The atheroscrerosis-related variables including Lp(a) and oxLp(a) were measured in 136 cardiovascular
disease-free subjects (61 males and 75 females, mean age of 64 years). The serum oxLp(a) level was quantified
using a sandwich ELISA system. The CIMT level was ultrasonographically measured on bilateral carotid arteries.
Results: The median level of Lp(a) was 120 μmol/L, oxLp(a) was 0.06 nmol/L, and CIMT was 0.7 mm, respectively.
A simple correlation test showed that the CIMT was significantly and positively correlated with age, systolic blood
pressure and oxLp(a) (r = 0.208, P < 0.05). A multiple linear regression analysis revealed that oxLp(a) continued to
show a significant and positive correlation with the CIMT (b = 0.202, P = 0.01). Although the similar analyses were
conducted for Lp(a), it showed only a weak correlation with the CIMT (r = 0.011, b = 0.041, both P < 0.05).
Conclusions: These results suggest that oxLp(a) may be more closely associated with accelerated carotid
atherosclerosis, in comparison to Lp(a), in this population. This finding can be important for obtaining a better
understanding of the different atherogenic roles played by oxLp(a) in comparison to Lp(a).
Introduction
The oxidation of lipids and lipoproteins is involved in
the pathogenesis of atherosclerosis [1]. Lipoprotein(a)
(Lp(a)) contains low-density lipoprotein (LDL)-like moi-
eties, in which the apoB-100 component is covalently
linked to the unique glycoprotein, apolipoprotein(a)
(apo(a)), and a high circulating level of Lp(a) is consid-
ered to be a risk factor for atherosclerotic diseases [2,3].
While the physiological role of Lp(a) in atherosclerotic
diseases remains incompletely understood, the oxidiza-
tion of Lp(a) may be one of the crucial clues that ather-
ogenesis has occurred. Of note, the existence of
oxidized phospholipids on Lp(a) in the circulation has
been reported to be strongly associated with coronary
artery disease [4]. The earlier studies used an assay sys-
tem that determines the content of oxidized phospholi-
pids per particle of apoB-100 and primarily per Lp(a),
and the results suggested that Lp(a) may participate in
the transfer of oxidized phospholipids [4]. We have also
identified oxidized Lp(a) (oxLp(a)) in human arteries
and blood using an assay system which employs a
unique antibody (161E2) to a specific epitope peptide of
nine residues (Arg-Asn-Pro-Asp-Ala-Val-Ala-Ala-Pro)
from the kringle-IV type 2 of apo(a) (this specific site is
hidden on native Lp(a) particles, but appears on Lp(a) in
the oxidative milieu) [5]. We have thus already accumu-
lated some data using this oxLp(a) measurement [5-8].
Although earlier experimental studies have revealed
that oxLp(a) can have more atherogenic properties than
native Lp(a) [5,9-14], there have so far been only limited
clinical studies using the serum oxLp(a) to investigate
the association between oxLp(a) and atherosclerotic
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any medium, provided the original work is properly cited.manifestations. More recently, two clinical studies have
been published about this association [6,8]. One study
reported that there was a significant and positive corre-
lation between the serum oxLp(a) and pulse wave velo-
city index (a measure of systemic arterial stiffness) in
hypertensive patients, and this correlation was relatively
greater than that between the serum Lp(a) and pulse
wave velocity index [6]. In addition, that study reported
that the oxLp(a) deposition was histochemically
detected, while the native Lp(a) deposition was not, in
the coronary calcified areas in patients with myocardial
infarction [6]. Another study reported that oxLp(a) was
histochemically detected in endothelial cells, similar to
native Lp(a), in human carotid and cerebral arteries, and
the deposition of oxLp(a), but not native Lp(a), was
abundant in the synthetic phase vascular smooth muscle
cells in the same arteries [8]. These findings indicate
that oxLp(a) can be more potent in the formation of
atherosclerosis throughout the early to progressive
stages of atherosclerosis than native Lp(a). These find-
ings warranted further evaluation of the significance of
oxLp(a) in the clinical settings.
The carotid arterial intima-media thickness (CIMT) is
frequently used in the clinic as one of the most repre-
sentative surrogate measures of cardiovascular disease
(CVD) risk [15,16]. Although we have previously
reported a non-significant correlation between the
serum oxLp(a) and CIMT, the study population in that
report included only healthy young females (mean age:
22 years) all of whom had very low CIMT levels (mean:
0.40 mm) [7]; therefore, it was difficult to assess the cor-
relation. Taking the background into account, the aim of
the present study was to investigate the relationship
between the levels of serum oxLp(a) and CIMT, in com-
parison to the serum Lp(a) levels, among asymptomatic
middle-aged and older subjects.
Subjects and Methods
A total of 136 Japanese subjects (mean age; 64 years,
range; 40-86 years) were enrolled in this study. The elig-
ibility criteria were: 1) asymptomatic, 2) without preg-
nancy, 3) neither regularly drank alcohol nor currently
smoked, 4) drug-free (including oral contraceptives and
over-the-counter drugs such as antioxidant agents), 5)
without any history of cardio/cerebrovascular, thyroid,
kidney or liver diseases. The Jichi Medical University
ethics committee approved the study, and each subject
gave informed consent.
The body mass index (BMI), seated systolic blood
pressure (SBP)/diastolic blood pressure (DBP) in the
upper-arm, plasma glucose and serum lipids/lipopro-
teins, including Lp(a) and oxLp(a), were measured.
Blood was sampled from the antecubital vein after an
overnight fast. The samples were immediately evaluated
for glucose and lipids, and the serum samples for eva-
luation of Lp(a) and oxLp(a) were frozen at -80°C until
they were used for measurement (within 3 months).
Glucose and lipids (LDL cholesterol [LDL-C], high-den-
sity lipoprotein cholesterol [HDL-C] and triglycerides
[TG]) were measured enzymatically, and the serum Lp
(a) was measured by an ELISA system (Shino-test Co.
Ltd., Japan) [17]. The assay system for Lp(a) uses only a
monoclonal antibody to a non-repeated segment of apo
(a), kringle-IV type 5, as both the solid-phase antibody
and the detecting capture antibody [17]. In addition, the
serum oxLp(a) level was quantified by a sandwich
ELISA system using an oxLp(a)-specific monoclonal
antibody (161E2) as both the solid-phase antibody and
the detecting capture antibody (we think that the use of
t h es a m ea n t i b o d yc a ni m p r ove the specificity of the
detection, because the specific epitope site is present at
≥ 2 locations in all apo(a) molecules), as previously
described [5,7]. This monoclonal antibody has been pro-
ven to react with only oxLp(a), but not native Lp(a) and
LDL [5]. For the measurement, the serum samples were
placed in each well of the Nunc-polystyrene microplates
coated with an anti-oxLp(a) monoclonal antibody. The
p l a t e sw e r ei n c u b a t e df o r1h o u ra tr o o mt e m p e r a t u r e ,
and after washing, were incubated for 1 hour at room
temperature with anti-oxLp(a) monoclonal antibody
labelled with a peroxidase conjugate. After washing,
3,3’,5,5’-tetra-methylbenzidine was added to each well,
and the enzymatic reaction was thereafter carried out
for 30 minutes at room temperature. After stopping the
reaction, the absorbance was read at 450 nm. The con-
centration of oxLp(a) was calculated based on the con-
centration of the bovine serum albumin (BSA)-peptide
that contributed 16 peptides per 1 molecule of BSA as a
standard [5]. The intra- and inter-assay coefficients of
variation were 1.2% and 5.0%, respectively.
The CIMT of the common carotid arteries was mea-
sured ultrasonographically b ya1 0 - M H zl i n e a rt y p eB -
mode probe (Aloka Co. Ltd., Japan). The CIMT, bilater-
ally measured in segments free of plaque (one at the
thickest site and another at two other points [1 cm
upstream and 1 cm downstream from the thickest site]),
was averaged for 3 measurements.
The data are expressed as the means ± standard devia-
tions or medians plus interquartile range. The correla-
tions between the CIMT and the other variables,
including Lp(a) and oxLp(a), were examined by Pear-
son’s correlation test as well as a multiple linear regres-
sion analysis adjusted for the measured variables (age,
g e n d e r ,B M I ,S B P ,L D L - C ,H D L - C ,T G ,g l u c o s e ) .O n l y
t h eS B Pw a se n t e r e di n t oam u l t i p l el i n e a rr e g r e s s i o n
analysis model because of its close collinearity with the
DBP (r ≥ 0.7). In the multiple linear regression analysis,
the values of TG, Lp(a), oxLp(a) and CIMT were
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skewed distribution. In addition, the tertile categories of
the serum Lp(a) or oxLp(a) levels as an explanatory vari-
able and carotid atherosclerosis (defined as a CIMT of >
1.0 mm [15]) as a criterion variable were entered into a
multivariate logistic regression model to estimate the
odds ratio (OR) and 95% confidential interval (CI) for
carotid atherosclerosis. The crude OR and OR adjusted
for the measured variables (age, gender, BMI, SBP, DBP,
LDL-C, HDL-C, TG, glucose) were determined. A P
value of ≤ 0.05 was considered to be significant.
Results
The subjects’ characteristics are presented in Table 1
and the correlations between Lp(a), oxLp(a) and the
other variables are listed in Table 2. A simple correla-
tion test showed a significant and positive correlation
between Lp(a) and oxLp(a) (r = 0.509, P < 0.0001). As
shown in Table 2, a simple correlation test showed a
significant and positive correlation between the patient
age and CIMT, as well as between the SBP and CIMT.
There was a significant and positive correlation between
the oxLp(a) and CIMT, while there was a non-signifi-
cant correlation between the Lp(a) and CIMT. Subse-
quently, a multiple linear regression analysis adjusted
for the measured variables revealed that there was a sig-
nificant, independent and positive correlation between
the CIMT and oxLp(a), but not Lp(a) level, in addition
to a significant, independent and positive correlation
between the patient age and CIMT, as well as between
the SBP and CIMT. We observed a weaker correlation
between the CIMT and the other variables, such as
LDL-C, relative to the correlation between the CIMT
and oxLp(a), in the multiple linear regression analysis.
In addition, a logistic regression analysis for carotid
atherosclerosis using the tertile of the Lp(a) or oxLp(a)
levels was carried out. There were 8 subjects with caro-
tid atherosclerosis in the 1
st tertile of Lp(a) (< 83 μmol/
L [n = 46]), 11 subjects with carotid atherosclerosis in
the 2
nd tertile of Lp(a) (83-192 μmol/L [n = 45]) and 8
subjects with carotid atherosclerosis in the 3
rd tertile of
Lp(a) (> 192 μmol/L [n = 45]). The crude OR (95%CI)
of Lp(a) was 1.0 (reference) in the 1
st tertile, 1.53 (0.55-
4.27, P = 0.41) in the 2
nd tertile and 1.03 (0.35-3.02, P =
0.96) in the 3
rd tertile. The multivariate-adjusted OR
(95%CI) of Lp(a) was 1.0 (reference) in the 1
st tertile,
1.80 (0.54-6.06, P = 0.34) in the 2
nd tertile and 1.08
(0.31-3.82, P = 0.91) in the 3
rd tertile. On the other
hand, there were 5 subjects with carotid atherosclerosis
in the 1
st tertile of oxLp(a) (< 0.03 nmol/L [n = 46]), 8
subjects with carotid atherosclerosis in the 2
nd tertile of
oxLp(a) (0.03-0.08 nmol/L [n = 45]) and 14 subjects
with carotid atherosclerosis in the 3
rd tertile of oxLp(a)
(> 0.08 nmol/L [n = 45]). The crude OR (95%CI) of
oxLp(a) was 1.0 (reference) in the 1
st tertile, 1.77 (0.53-
5.90, P = 0.35) in the 2
nd tertile and 3.70 (1.21-11.38, P
= 0.02) in the 3
rd tertile. The multivariate-adjusted OR
(95%CI) of oxLp(a) was 1.0 (reference) in the 1
st tertile,
2.72 (0.73-10.18, P = 0.14) in the 2
nd tertile and 3.60
(1.01-12.92, P = 0.048) in the 3
rd tertile. Therefore, the
subjects with the highest tertile of oxLp(a), but not Lp
(a), had a significantly and independently high OR for
the presence of carotid atherosclerosis.
Discussion
The present study showed that the serum oxLp(a) level
was a significant, independent and positive measure of
carotid atherosclerosis, as assessed by the CIMT, in
comparison to the serum Lp(a) level, in asymptomatic
subjects. A weak correlation between the Lp(a) and
CIMT, and a relatively low level of Lp(a) (compared to
an earlier study of a general Japanese population [18])
were observed in this study. This may be, in part, due to
the studied population, all of whom were asymptomatic
and of possibly good health, as well as due to the Lp(a)
detection method using the antibody to a non-repeated
segment of apo(a), which is not affected by apo(a) size
polymorphisms [17]. While the impact of oxLp(a) on
carotid atherosclerosis was clear in the subjects with the
highest tertile of oxLp(a), the circulating level of oxLp(a)
was lower than that of Lp(a) and the correlation
between the oxLp(a) and CIMT was not very strong as
an overall finding. Therefore, the clinical relevance of
the results will need to be confirmed in further studies.
However, this finding obtained by the use of the CIMT
is valuable because carotid atherosclerosis is a well-
known clinical predictor of the CVD risk [15,16]. Of
note, the present findings suggest that high serum levels
of oxLp(a) may be associated with accelerated athero-
sclerosis, which provides important information for
Table 1 The clinical characteristics of the study subjects
Variable Levels
Age, years 64 ± 11
Male/female, n 61/75
Body mass index, kg/m
2 24.7 ± 3.8
Systolic blood pressure, mmHg 129 ± 14
Diastolic blood pressure, mmHg 79 ± 10
Low-density lipoprotein cholesterol, mmol/L 2.98 ± 0.75
High-density lipoprotein cholesterol, mmol/L 1.41 ± 0.38
Triglycerides, mmol/L 1.33 (0.97-1.95)
Glucose, mmol/L 6.44 ± 2.19
Lp(a), μmol/L 120 (70-230)
Oxidized Lp(a), nmol/L 0.06 (0.03-0.12)
CIMT, mm 0.7 (0.6-0.9)
CIMT: carotid artery intima-media thickness. The data are expressed as the
means ± standard deviations, medians plus interquartile range (for
triglycerides, Lp(a), oxidized Lp(a) and CIMT) or subject number.
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genic roles played by oxLp(a) in comparison to Lp(a), in
addition to the earlier knowledge about the clinical asso-
ciations among Lp(a), oxLp(a) and atherosclerotic mani-
festations [6,8].
The precise reason for the association between the
serum oxLp(a) and CIMT in this study was unclear,
although a possible mechanism has been suggested. One
experimental study reported the generation of O
2- (pro-
moting oxidative stress) in oxLp(a)-treated rabbit renal
arteries, which could lead to endothelial dysfunction
(this occured in the oxLp(a)-, but not native Lp(a)-,
treated rabbits) [11]. One clinical study showing a signif-
icant and positive correlation between the oxLp(a) and
pulse wave velocity in hypertensive patients assumed
that the oxidative status of hypertension could contri-
bute to that correlation [6]. Another histochemical
study on human carotid arteries reported the presence
of oxLp(a) in the endothelial cells and subendothelial
layers, indicating that native Lp(a) is initially oxidized or
that oxLp(a) is initially taken up from the blood into the
endothelial cells and subendothelial layers [8]. Moreover,
that study implicated oxLp(a) as having more involve-
ment, relative to native Lp(a), in the progression of
arthrosclerosis, based on the abundant presence of oxLp
(a) in the synthetic phase vascular smooth muscle cells
[8]. In general, oxidative stress induces increases in the
CIMT, and the increased CIMT can further enhance the
oxidative stress, leading to a vicious cycle (this cycle
may be essentially pronounced during the progressive
stage of arthrosclerosis) [19]. In addition, it is thought
that Lp(a) can be atherogenic in relation to oxidized
molecules, such as oxidized phospholipids, under the
oxidative milieu, where the oxidation of Lp(a) may be
promoted [4]. In this context, we hypothesize that once
oxLp(a) is present, it induces an oxidative condition,
and this condition increases the CIMT, and a vicious
cycle of oxLp(a)-CIMT elevation occurs as a result.
There are several limitations to this study. The study
population was restricted to asymptomatic subjects, not
an obviously diseased population. The cross-sectional
design of the study did not clearly elucidate the cause-
and-effect on the results. In addition, the residual con-
founding factors that can affect the oxidative status and/
or the oxidation of lipoproteins (i.e., dietary factors)
were not available in the study. Therefore, future studies
with different populations, prospective designs and the
inclusion of many confounders will be necessary to
establish our findings.
Conclusions
In summary, the serum oxLp(a) was more significantly,
independently and positively correlated with the CIMT
than the serum Lp(a), in asymptomatic middle-aged and
older subjects. This finding seems to be important for
obtaining a better understanding of the different athero-
genic roles played by oxLp(a) in comparison to Lp(a) in
the pathogenesis of atherosclerosis. Further studies are
required to determine the observed relationship and to
clarify the biological mechanisms involved in this
relationship.
Acknowledgements
This study was supported in part by a Grant-in-Aid for the Scientific
Research from the Ministry of Education, Culture, Sports, Science, and
Technology of Japan (K.K) and the Foundation for the Development of the
Community, Japan.
Author details
1Department of Clinical Laboratory Medicine, Jichi Medical University,
Tochigi, Japan.
2Central Research Institute, Shino-Test Corporation, Kanagawa,
Japan.
3Saitama Memorial Hospital, Saitama, Japan.
Table 2 The correlations between the CIMT and Lp(a) or oxidized Lp(a) level
For Lp(a) For oxidized Lp(a)
Variable Simple (P) Multi-adjusted (P) Multi-adjusted (P)
Age, years 0.415 (< 0.0001)** 0.426 (< 0.0001)** 0.423 (< 0.0001)**
Gender, male 0.072 (0.402) 0.085 (0.297) 0.058 (0.468)
Body mass index, kg/m
2 0.039 (0.652) - 0.019 (0.809) - 0.015 (0.851)
Systolic BP, mmHg 0.253 (0.003)** 0.230 (0.005)** 0.223 (0.006)**
Diastolic BP, mmHg 0.132 (0.124) - -
LDL cholesterol, mmol/L - 0.018 (0.831) 0.106 (0.208) 0.100 (0.224)
HDL cholesterol, mmol/L - 0.001 (0.993) - 0.006 (0.943) - 0.019 (0.822)
Triglycerides, mmol/L - 0.043 (0.616) 0.015 (0.872) 0.024 (0.792)
Glucose, mmol/L 0.062 (0.476) 0.021 (0.809) 0.031 (0.708)
Lp(a), μmol/L 0.011 (0.901) 0.041 (0.625) -
Oxidized Lp(a), nmol/L 0.208 (0.015)* - 0.202 (0.010)**
CIMT: carotid artery intima-media thickness, BP: blood pressure, LDL: low-density lipoprotein, HDL: high-density lipoprotein. Simple: Pearson’s correlation
coefficient (r), multi-adjusted: a multiple linear regression coefficient (b). The CIMT, triglycerides, Lp(a) and oxidized Lp(a) levels were calculated after a log-
transformation. Significance level: * P ≤ 0.05, ** P ≤ 0.01.
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